Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Multi-centre, Phase I/II Dose Escalation Trial of a Recombinant Adeno-associated Virus Vector (AAV2/8-hG1.7p.coCNGA3) for Gene Therapy of Children and Adults With Achromatopsia Owing to Defects in CNGA3

NCT03758404 is registered in ClinicalTrials.gov with MeiraGTx UK II Ltd as lead sponsor.

NCT NCT03758404
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03758404 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Multi-centre, Phase I/II Dose Escalation Trial of a Recombinant Adeno-associated Virus Vector (AAV2/8-hG1.7p.coCNGA3) for Gene Therapy of Children and Adults With Achromatopsia Owing to Defects in CNGA3
Lead sponsor
MeiraGTx UK II Ltd
Phase
Phase 1/2
Overall status
Completed
Start date
August 12, 2019
Completion date
June 10, 2021
Enrollment
11 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

achromatopsia